Reset filters
13 February 2025

Female sex increases risk of Group I pulmonary arterial hypertension by roughly threefold, but the mechanism is unclear. Low expression of Cyp1b1, an enzyme that metabolizes estrogens, is associated with disease penetrance, particularly in women. We previously found that lower Pparγ levels in murine PAH models, which may drive disease, are rescued by estrogen blockade.

Pulmonary Circulation
8 February 2025

Resting heart rate has been incorporated in REVEAL risk assessment. Rest and sleep heart rate variability (HRV) measured in the home setting could provide early insight into worsening physiology in patients with pulmonary arterial hypertension (PAH). 

Pulmonary Circulation
3 February 2025

My first clinical experience with Pulmonary Hypertension occurred when, as a resident at Duke University Hospital in the late 1970's, a patient with “primary pulmonary hypertension (PPH)” was admitted with right heart failure.

Pulmonary Circulation